Esbriet

Jefferies & Company has published a research report on InterMune (NASDAQ: ITMN) after Germany's Federal Joint Committee released its final assessment on Esbriet. In the report, Jefferies writes, "This morning Germany's Federal Joint Committee (G-BA) issued final assessment on clinical benefit...

Shares of InterMune, Inc. (Nasdaq: ITMN) surged more than 60% after a panel at the Food and Drug Administration recommended the company's Esbriet for treatment of idiopathic pulmonary fibrosis. IPF is a rare and deadly lung disease with no existing FDA approved treatments, which affects nearly 200,...

Wells Fargo Securities analysts Aaron Reames and Matthew J. Andrews rated shares of InterMune, Inc. (Nasdaq: ITMN) Market Perform. The analysts questioned whether or not the FDA would accept InterMune's use of Forced Vital Capacity, as opposed to Overall Survival as the appropriate endpoint for the...